Targeted therapies were not developed as a result of genomics. Erlotinib was <i>approved</i> in 2005. We&#x27;ve had Sanger sequencing assays for EGFR, BRAF etc for years, and they&#x27;re still standard of care. We can identify resistance mutations, but we often don&#x27;t know what to do with this information. Your patient becomes resistant, you identify the causative variants, you watch your patient progress and die.<p>Sure, genomics gives us a comprehensive way to sequence, but my point is that it did not yield the sudden, vast sweep of insights that we expected it would.